R&D

RIP tanezumab? Eli Lilly, Pfizer spotlight alarming safety data for NGF pain drug in PhIII

Discovery

Penn scientists correct genetic flaw in mice fetuses, expanding in utero CRISPR reach to lung diseases

Startups, Venture

Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA
More news caret

calendar Protocols

Quick hits from around the biopharma web

Apr 18

Genfit wins BTD status at FDA for its lead drug for liver disease; Idorsia outlines $530M '19 spending plans on late-stage R&D

Apr 17

Turning Point unveils $166M IPO; Aquestive's riluzole film product is accepted for FDA review

Apr 16

NICE backs Akcea's Tegsedi; EMA restricts Lemtrada use while it probes safety concerns

Apr 15

Insys promotes CFO to the helm as Saeed Motahari hits the exit; Gelesis gets OK to market weight loss treatment

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Apr 18

Peer Review: KSQ woos Beni Wolf from Blueprint with CRISPR platform; AstraZeneca exec jumps to CNS biotech spun out of Takeda

Apr 12

Peer Review: Leaving Cerecor after a year, Peter Greenleaf starts a new CEO chapter at Aurinia — out to slay Restasis

Apr 5

Peer Review: Plotting US moves, Zealand Pharma poaches Alnylam's Emmanuel Dulac as new CEO

Mar 29

Sunao Manabe takes top job at Daiichi Sankyo in wake of AstraZeneca deal; CAR-T player Celyad promotes Filippo Petti to CEO

More peer review caret

Dollar Premium

Going gangbusters: The top 20 biotech platform deals by upfront cash

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

bullhorn Bioregnum

The view from John Carroll

Apr 17

Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did

Apr 15

SCOTUS just turned its back on Allergan’s legal maneuver to take a blow at inter partes review. What did you expect?

Apr 12

Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med

Apr 8

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

More opinion caret

twitter Marco

Top biopharma links on Twitter - last updated ago

arrow-thick Most Viral

Disappointing trial results dim hopes for a new class of pain drugs - STAT

STAT a day

Second death in Novartis gene therapy trials under investigation

Reuters Deena Beasley a day

10 Years As CEO: 3 Guiding Principles That Transformed Exact Sciences

Linkedin a day

FDA approves first generic naloxone nasal spray to treat opioid overdose

FDA a day

Biopharma company deal transactions soar in first quarter

BioWorld a day

Crowd Innovation for Artificial Intelligence-Based Solutions for Radiation Therapy Targeting

JAMA a day

Polygenic Risk Scores Expand to Obesity

ScienceDirect a day

Why academics are calling for replacing biosimilars with price regulation

BioCentury a day

Experts Seek Alignment of Standards Recognition Across FDA's CDER, CBER, CDRH

RAPS a day

This Genetic Mutation Makes People Feel Full - All the Time

New York Times Gina Kolata a day

timer Latest

STAT

A pivotal test of an experimental malaria vaccine set to begin - STAT

JAMA

Crowd Innovation for Artificial Intelligence-Based Solutions for Radiation Therapy Targeting

FDA

FDA approves first generic naloxone nasal spray to treat opioid overdose

ScienceDirect

Polygenic Risk Scores Expand to Obesity

STAT

Disappointing trial results dim hopes for a new class of pain drugs - STAT

BioCentury

Why academics are calling for replacing biosimilars with price regulation

The Scientist Magazine®

Base Editors Cause Off-Target Mutations in RNA

BioWorld

Biopharma company deal transactions soar in first quarter

New York Times

Purdue Pharma and Sacklers Reach $270 Million Settlement in Opioid Lawsuit

BioSpace

United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug | BioSpace

fire Hot This Week

1

Fast Edgar

Marker Therapeutics Form 8-K

2

NPR.org

First U.S. Patients Treated With CRISPR As Gene-Editing Human Trials Get Underway

3

STAT

It's just in mice! This scientist is calling out hype in science reporting - STAT

4

STAT

A startup's goal: Kill cancer with pills targeting RNA, not proteins - STAT

5

Xconomy

Xconomy: It's Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help

6

FierceBiotech

Wotton replaces Gilman as CEO of cell, gene therapy startup Obsidian

7

STAT

Disappointing trial results dim hopes for a new class of pain drugs - STAT

8

investors-hub

Biotech Values Post # 224656: Recent Biotech Bankruptcies/Liquidations/Dissolutions

9

STAT

Stanford clears three faculty members of 'CRISPR babies' involvement

10

STAT

Most people pay $5 per month or less for the drug. But some pay $11,002

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back